US 11,911,382 B2
Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
Steve Wring, South Boston, VA (US); Magdalena Alonso-Galicia, Durham, NC (US); Thomas Pack, Durham, NC (US); Julie Rurka, Raleigh, NC (US); David Carpenter, Durham, NC (US); and Melissa Rhodes, Raleigh, NC (US)
Assigned to Altavant Sciences GmbH, (CH)
Filed by Altavant Sciences GmbH, Basel (CH)
Filed on Jul. 18, 2022, as Appl. No. 17/813,173.
Application 17/813,173 is a continuation of application No. 16/685,165, filed on Nov. 15, 2019, granted, now 11,413,287.
Claims priority of provisional application 62/768,575, filed on Nov. 16, 2018.
Prior Publication US 2023/0000866 A1, Jan. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61P 9/00 (2006.01); A61P 9/12 (2006.01); A61P 11/00 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 9/0053 (2013.01); A61P 9/12 (2018.01)] 8 Claims
 
1. A method of inhibiting the formation of 5-HT in a human patient comprising:
administering to the patient a therapeutically effective amount of a compound of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof,
wherein the compound is in substantially crystalline form, and
wherein the therapeutically effective amount is about 1 mg/kg/day to about 50 mg/kg/day.